← Back to Patent Explorer
US4997443A Expired / Lapsed US ⏱️ 0.0 years remaining

Transplantable artificial tissue and process

Assignee: Somatix Therapy Corp
•
Filing: 1989-12-04
•
Granted: 1991-03-05
•
Expires: 2009-12-04
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A transplantable artificial tissue matrix structure containing viable cells which is suitable for insertion into the body is made by polymerizing precursors in an aqueous solution to form a shape retaining solid matrix comprising viable cells, matrix polymer and reversible gel polymer. The solution contains a matrix polymer precursor, a reversible gel polymer precursor, and viable cells. The reversible gel polymer is dissolved and removed to yield an insoluble, porous matrix containing viable cells. The conditions and reagents are selected to maintain the viability of the cells. The invention is particularly suitable for artificial transplant matrix tissue containing pancreatic islet cells.

Inventors

  • 👤 Bennie J. Walthall
  • 👤 Yvonne E. McHugh
  • 👤 Houston F. Voss

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 04:55
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/14; A61L27/22; A61K; A61K35/00; A61K35/12; A61K35/37; A61K35/39; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1652; A61K9/1658; A61K9/1682; A61K9/1694; A61L27/50; A61L27/60

Claims Analysis

Total Claims: 20
Claim 1
Independent Claim 82 words
A process for making a transplantable artificial tissue matrix comprising (a) polymerizing polymer precursors in an aqueous solution containing a matrix polymer precursors, a reversible gel polymer precursor, and viable cells to form a shape retaining solid matrix comprising viable cells, matrix polymer and reversible gel polymer, (b) dissolving and removing gel polymer from the matrix, and (c) recovering an insoluble, porous matrix containing viable cells, wherein the conditions an reagents are selected to not significantly impair the viability of the cells.
Claim 2
Dependent Claim 82 words
A process for making a transplantable artificial tissue matrix comprising (a) polymerizing polymer precursors in an aqueous solution containing a matrix polymer precursors, a reversible gel polymer precursor, and viable cells to form a shape retaining solid matrix comprising viable cells, matrix polymer and reversible gel polymer, (b) dissolving and removing gel polymer from the matrix, and (c) recovering an insoluble, porous matrix containing viable cells, wherein the conditions an reagents are selected to not significantly impair the viability of the cells.
Claim 3
Dependent Claim 27 words
The process of claim 1 wherein the matrix polymer precursor is selected from the group consisting of plasma, fibrinogen, casein, fibrin, limulus lysate, milk protein and collagen.
Claim 4
Dependent Claim 27 words
The process of claim 1 wherein the matrix polymer precursor is plasma, and the matrix polymer polymerization is effected by mixing the plasma with Ca +2 ions.
Claim 5
Dependent Claim 23 words
The process of claim 2 wherein the matrix polymer precursor is fibrinogen and the polymerization is effected by mixing the fibrinogen with thrombin.
Claim 6
Dependent Claim 30 words
The process of claim 2 wherein the matrix polymer precursor is caesin or mil protein and the polymerization is effected by mixing the matrix polymer precursor with renin or pepsin.
Claim 7
Dependent Claim 24 words
The process of claim 2 wherein the matrix polymer precursor is fibrin and the polymerization is effected by mixing the fibrin with Factor XIIIa.
Claim 8
Dependent Claim 36 words
The process of claim 2 wherein the matrix polymer precursor is collagen and the polymerization is effected by raising the temperature of the collagen solution to from 37 to 55C while maintaining a neutral solution pH.
Claim 9
Dependent Claim 14 words
The process of claim 1 wherein the reversible gel polymer precursor is a polysaccharide.
Claim 10
Dependent Claim 40 words
The process of claim 8 wherein the reversible gel polymer precursor is an alginate or a polysaccharide gum, and the polymerization of the reversible gel polymer precursor is effected by mixing the reversible gel polymer precursor with Ca +2 ions.
Claim 11
Dependent Claim 51 words
The process of claim 9 wherein the gel polymer in the matrix is dissolved by reducing the concentration of Ca +2 ions an aqueous solution containing the matrix by mixing the solution with a sequestering agent or cation exchange resin capable of binding Ca +2 ions, to depolymerize the gel polymer.
Claim 12
Dependent Claim 32 words
The process of claim 8 wherein the reversible gel polymer precursor is agarose, the polymerization is effected by decreasing the temperature of the agarose solution to a level which promotes agarose polymerization.
Claim 13
Dependent Claim 33 words
The process of claim 11 wherein the reversible gel polymer in the matrix is dissolved by elevating the temperature of an aqueous solution containing the matrix to a level which promotes agarose depolymerization.
Claim 14
Dependent Claim 25 words
The process of claim 11 wherein the reversible gel polymer in the matrix is dissolved by mixing an aqueous solution containing the matrix with agarase.
Claim 15
Dependent Claim 33 words
The process of claim 8 wherein the polysaccharide is a member selected from the group consisting of agarose, carrageenan, agar, alginate, guar gum, gum arabic, pectin, tragacanth gum, xanthan gum and mixtures thereof.
Claim 16
Dependent Claim 10 words
The matrix composition produced by the process of claim 1.
Claim 17
Dependent Claim 14 words
The matrix composition of claim 1 wherein the viable cells are pancreatic islet cells.
Claim 18
Dependent Claim 154 words
A process for making a transplantable artificial tissue matrix comprising (a) polymerizing polymer precursors in an aqueous solution containing a matrix polymer precursor, a reversible gel polymer precursor, and viable cells to form a shape retaining solid matrix comprising viable cells, matrix polymer and reversible gel polymer, (i) wherein said matrix polymer precursor is selected from the group consisting of plasma, fibrinogen, casein, fibrin, limulus lysate, milk protein and collagen and mixtures thereof, and (ii) said reversible gel polymer is a member selected from the group consisting of agarose, carrageenan, agar, alginate, guar gum, gum arabic, pectin, tragacanth gum, xanthan gum and mixtures thereof. (b) dissolving and removing gel from the matrix by exposing the matrix to a solution having characteristics which effect depolymerization of the gel polymer, and (c) recovering an insoluble, porous matrix containing viable cells, wherein the conditions and reagents are selected to not significantly impair the viability of the cells.
Claim 19
Dependent Claim 154 words
A process for making a transplantable artificial tissue matrix comprising (a) polymerizing polymer precursors in an aqueous solution containing a matrix polymer precursor, a reversible gel polymer precursor, and viable cells to form a shape retaining solid matrix comprising viable cells, matrix polymer and reversible gel polymer, (i) wherein said matrix polymer precursor is selected from the group consisting of plasma, fibrinogen, casein, fibrin, limulus lysate, milk protein and collagen and mixtures thereof, and (ii) said reversible gel polymer is a member selected from the group consisting of agarose, carrageenan, agar, alginate, guar gum, gum arabic, pectin, tragacanth gum, xanthan gum and mixtures thereof. (b) dissolving and removing gel from the matrix by exposing the matrix to a solution having characteristics which effect depolymerization of the gel polymer, and (c) recovering an insoluble, porous matrix containing viable cells, wherein the conditions and reagents are selected to not significantly impair the viability of the cells.
Claim 20
Dependent Claim 10 words
The matrix composition produced by the process of claim 17.

References Cited (Backward Citations)

US4647536A Cited
US4526867A Cited
US4798786A Cited
US4504582A Cited
US4645669A Cited
US4689293A Cited
US4861714A Cited
US4722898A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-03-04 1994-09-03 1995-03-05 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-03-04 1998-09-03 1999-03-05 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-03-04 2002-09-03 2003-03-05 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag